2021

2021

• August 5, 2021 - VBL Therapeutics to Report Second Quarter Financial Results on August 16
• July 22, 2021 - VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors
• July 8, 2021 - VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
• June 15, 2021 - VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
• June 3, 2021 - VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
• May 20, 2021 - VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
• May 11, 2021 - VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
• May 4, 2021 - VBL Therapeutics to Report First Quarter Financial Results on May 11
• April 14, 2021 - Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants
• April 9, 2021 - Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre- Funded Warrants
• April 8, 2021 - Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
• March 31, 2021 - VBL Therapeutics to Host Virtual R&D Day on April 6
• March 25, 2021 - VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
• March 17, 2021 - VBL Therapeutics to Report Fourth Quarter and Full Year Financial Results on March 25
• March 8, 2021 - VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences
• March 4, 2021 -
• March 1, 2021 - VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme
• February 22, 2021 - VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
• January 27, 2021 - VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients
• January 15, 2021 - VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC